PTX100 - Driving the future

There is a lot of negative chatnon this forum, so I've created a new thread to celebrate the PTX successes

PTX200
- High overall success rate in Ph2a breast cancer trial
- Encouraging ovarian cancer trial data
- AML trial results showing complete response

The team will expand this work to bigger sample sizes ehich is what the broader community is asking for

PTX100
- First patients have been dosed and results will intermittently drop over the 1H2020. Most likely Q1..
- There is a real unmet need in the RAS and RhoA mutation space and for me this is where the real excitement lies with this company.

When they start dropping results from their basket studies, this company is going to be one of the great sucess stories of 2020.

For those who want out, or want to take profit, I completely understand.
But for those like me who believe in the science, these low prices represent an opportunity to accumulate and wait patiently.

All IMO and DYOR

HNY